Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Inclusion Criteria: * ADPKD patient older then 40 years of age without gender limitation * Estimated glomerular filtration rate (eGFR) higher than 60 ml/min 1.73m2 * documented kidney volume progression with yearly increasing rate more than 6% * informed consent Exclusion Criteria: * Female who is planning to become pregnant, who is pregnant and/or lactating, who is unwilling to use effective means of contraception * impaired liver function as increased liver enzymes (2-fold above normal values) * uncontrolled hypercholesterolemia (fasting cholesterol \> 8 mmol/l) or hypertriglyceridaemia (\> 5 mmol/l) under lipid lowering therapy * granulocytopenia (white blood cell \< 3,000/mm3) or thrombocytopenia (platelets \< 100,000/mm3) * hepatitis B or C, HIV infection * malignancy * mental illness that interfere with the patient ability to comply with the protocol * drug or alcohol abuse * known hypersensitivity to similar drugs as Triptolide-Containing Formulation